FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 248 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR EMA Recommends Extending Indications for Zanubrutinib to Include Treatment of Patients... November 2, 2023 The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable... July 1, 2021 Cancer research in 2020: A spotlight on Manchester December 27, 2020 COVID-19, Cancer, and Uncertainty: An Oncologist’s Perspective on Coping November 17, 2020 Load more HOT NEWS Managing Side Effects with South Asian Foods Making Important Decisions During Cancer: A Survivor’s Story Shannon’s Law Requires NY Insurance Companies to Cover Mammograms for Ages... Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in...
